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Background: Asthma is a heterogeneous disease and development of novel therapeutics requires an understanding
of pathophysiologic phenotypes. The purpose of the ADEPT study was to correlate clinical features and biomarkers
with molecular characteristics, by profiling asthma (NCT01274507). This report presents for the first time the study
design, and characteristics of the recruited subjects.
Methods: Patients with a range of asthma severity and healthy non-atopic controls were enrolled. The asthmatic
subjects were followed for 12 months. Assessments included history, patient questionnaires, spirometry, airway
hyper-responsiveness to methacholine, fractional exhaled nitric oxide (FENO), and biomarkers measured in induced
sputum, blood, and bronchoscopy samples. All subjects underwent sputum induction and 30 subjects/cohort
had bronchoscopy.
Results: Mild (n = 52), moderate (n = 55), severe (n = 51) asthma cohorts and 30 healthy controls were enrolled from
North America and Western Europe. Airflow obstruction, bronchodilator response and airways hyperresponsiveness
increased with asthma severity, and severe asthma subjects had reduced forced vital capacity. Asthma control
questionnaire-7 (ACQ7) scores worsened with asthma severity. In the asthmatics, mean values for all clinical and
biomarker characteristics were stable over 12 months although individual variability was evident. FENO and
blood eosinophils did not differ by asthma severity. Induced sputum eosinophils but not neutrophils were
lower in mild compared to the moderate and severe asthma cohorts.
Conclusions: The ADEPT study successfully enrolled asthmatics across a spectrum of severity and non-atopic
controls. Clinical characteristics were related to asthma severity and in general asthma characteristics e.g. lung
function, were stable over 12 months. Use of the ADEPT data should prove useful in defining biological phenotypes to
facilitate personalized therapeutic approaches.
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Asthma is a highly-prevalent heterogeneous disease
characterized by variable airflow obstruction with cough,
dyspnea and wheezing. Patients are also at risk of exacer-
bations which may lead to hospitalization and in rare
circumstances death. While there are many proposed
asthma phenotypes, the underlying biology of these
phenotypes remains poorly understood.
A subset of the asthma population has severe asthma,
sometimes termed refractory asthma [1], which is in-
completely responsive to currently available therapies.
In combination with bronchodilators, the most effective
therapies for asthma are anti-inflammatory in their
action including most notably inhaled corticosteroids
(ICS) and the monoclonal antibody (MAb) omalizumab
(anti-IgE) [2]. Recently, MAb’s against interleukin- 4
(IL-4) receptor (IL-4R) [3], IL- 5 [4, 5], and IL-13 [6]
have demonstrated efficacy by improving lung function
and reducing exacerbations when administered in addition
to standard therapies in severe asthma. Highlighting the
importance of phenotyping, these therapeutics have en-
hanced efficacy in subjects selected using eosinophil- or
type 2 immunity- associated markers e.g. serum periostin
(POSTN), sputum and blood eosinophils (spEOS, bEOS),
serum IgE (sIgE), and the fractional concentration of ex-
haled nitric oxide (FENO).
Airway inflammation, airflow obstruction, and airway
hyper-responsiveness (AHR) represent major compo-
nents of asthma pathophysiology [7]. Different inflam-
matory pathways may explain why most therapies are
only effective in a subset of patients. Accordingly, diag-
nostic biomarkers are needed to appropriately classify
patients and enable selection of a more targeted ther-
apy for each phenotype. Such biomarkers are most eas-
ily assessed for clinical purposes in blood, exhaled
breath, or urine. Other sampling methods such as in-
duced sputum (IS) and bronchoscopy are only available
in specialized centers. Response to ICS, for example,
can be predicted by FENO [8], spEOS [9] and a 3-gene
signature (CLCA1, POSTN, and serpinB2) in epithelial
brushings [10].Table 1 Categorization of asthma severity based upon background





None Eligible for mild
asthma cohort
Inelig
Low to medium ICS alone or in combination




High dose ICS alone or in combination with
other controllers including chronic oral
corticosteroids and omalizumab
Ineligible Eligib
asthmThe primary objective of the ADEPT study was to
determine molecular and cellular profiles in periph-
eral blood, urine, induced sputum, and bronchial tis-
sue across the spectrum of asthma severity and to
enable the correlation of molecular subtyping with ac-
cessible clinical characteristics.
The goal of this report is to present for the first
time the ADEPT asthma study design which enrolled
asthma subjects of different severities and non-atopic
healthy controls, and to describe subject characteris-
tics and biomarkers.
Methods
The study received ethical approval from the ethics
committees of each of the sites involved. All subjects
provided written informed consent to participate (genomic
DNA testing was optional). The clinicaltrials.gov identifier
is NCT01274507. The full study protocol is linked to this
report.
Population
Approximately 150 asthmatic subjects (50 subjects in
each of 3 asthma categories (mild, moderate, severe) and
30 non-atopic healthy controls were planned for inclu-
sion in the study. The National Heart, Lung, and Blood
Institute (NHLBI) expert panel report [11] was adapted
for classification of severity based on lung function and
controller medication levels (Table 1). All subjects were
non-smokers, or had quit for ≥ 1 year at initial screening
visit and had a ≤ 10 pack-year history of smoking. A
history of COPD or any other significant pulmonary
disease was exclusionary. Imaging was not performed
for this study, nor were prior imaging results collected.
Mild asthma was defined as pre-bronchodilator forced
expired volume in 1 s (FEV1) ≥ 80 % predicted values
measured >6 h after the last use of bronchodilator and
no asthma controller medication in the 6 weeks prior to
screening, with short acting β-2 agonist (SABA) on an
as-needed basis permitted (modified NHLBI STEP 1)
[11]. This group allowed evaluation of biomarkers with-
out the influence of corticosteroids.therapy and lung function
D FEV1≥ 60- < 80 %
icted normal
Pre-BD FEV1≥ 50- < 60 %
predicted normal











Silkoff et al. Respiratory Research  (2015) 16:142 Page 3 of 15Moderate persistent asthma was defined as pre-
bronchodilator FEV1 from ≥ 60 to < 80 % predicted
values measured > 6 h after the last use of any bron-
chodilator, treatment with SABA as needed, and low
to medium dose ICS, based on NHLBI definitions
[11], alone, or in combination with any other control-
ler medication (e.g. long-acting β-2 agonists (LABA),
leukotriene modifying agents, theophylline) with the ex-
ception of oral corticosteroids (OCS), or omalizumab
(modified NHLBI STEP 2, 3, or 4;) [11].
Severe persistent asthma was defined as pre-
bronchodilator FEV1 from ≥ 50 to <80 % predicted
values measured > 6 h after last use of bronchodilator,
treatment with SABA, and high dose ICS alone or in
combination with any other controller medication in-
cluding OCS, and/or omalizumab, (modified NHLBI
STEP 5 or 6) [11].
Inclusion criteria
All inclusion and exclusion criteria are listed in the
study protocol (Additional file 1) linked to this report.
Asthmatic subjects not participating in bronchoscopy
were between 18 and 70 years old while those enrolled
in the bronchoscopy cohort were 18–55 years old.
Asthmatics were required to have principal investigator
confirmation of a history of asthma with asthma symp-
toms for ≥6 months prior to screening, and exclusion
of alternative diagnoses. There was no required level of
asthma control, but subjects undergoing bronchoscopy
had to be clinically stable for at least 6 weeks. Subjects
had to meet at least 1 of the following three criteria
tested sequentially:
1) Bronchodilator reversibility (BDR) defined as a FEV1
increase of at least 12 % and 200 mls after a SABA
OR
2) The provocative concentration (PC20) of
methacholine resulting in a 20 % or greater fall in
the FEV1 < 16 mg/mL. PC20 could also have been
documented within the previous 24 months.
Assessment of PC20 required a pre-bronchodilator
(pre-BD) FEV1 of at least 60 % predicted.
OR
3) Airflow obstruction defined as a pre-BD FEV1/
forced vital capacity (FVC) ratio <0.7 (for those
with no BDR and unable to undergo PC20 testing
due to low FEV1).
Healthy controls were 18–55 years old, non-
smokers, and were required to be non-atopic based
on a specificIgE panel, ImmunoCap Phadiatop™,
(Phadia AB, Uppsala, Sweden). The healthy controls
were required to have normal lung function (FEV1 %
predicted of normal >85 %) and a BDR <12 % and<200 ml, Additionally, healthy controls were had no
clinically significant abnormalities as determined by
medical history, physical examination, blood chemis-
try assessments, hematologic assessments including
complete blood count (CBC), urinalysis, measure-
ment of vital signs, and ECG. Specifically, they were
also required to have no history of allergic symptoms
e.g., allergic rhinitis, or eczema.
Study design and visits
Asthma
A study design schematic is shown in Fig. 1. Asthmatic
subjects underwent screening, then if enrolled attended
the baseline visit. For subjects included in the bron-
choscopy study, the bronchoscopy visit occurred within
~2 weeks of the baseline visit. Further clinical assess-
ment/biomarker visits occurred at 3, 6 and 12 months,
with induced sputum sampling repeated at the 6 month
visit. These 3, 6 and 12 month visits were included to
evaluate variability over time and also the impact of
seasons.
The study procedures for asthmatic participants are
detailed in the protocol linked to this report and were
completed at several visits as necessary. The Screening
Period included review of inclusion/exclusion criteria,
obtaining consent, history and physical examination,
vital signs, lung function testing, blood tests, and an
acceptable sample of sputum obtained by induction
was required from all study participants. PC20 metha-
choline testing was performed in asthmatics during
screening if it was required for confirmation of asthma
for inclusion into the study, provided prebronchodila-
tor FEV1 was at least 60 % predicted. At the first visit
after enrollment (i.e. the baseline visit) clinical and
biomarker parameters, induced sputum and PC20
methacholine (in those who didn’t have this per-
formed during screening) were assessed. The bron-
choscopy visit was scheduled 5–14 days after the
baseline visit to enable comparison of sputum and
bronchoscopy samples within a short timeframe.
Approximately 30 subjects of each asthma severity co-
hort underwent bronchoscopy to obtain endobronchial
biopsy (EBBX) and epithelial brushing (EPBR) samples.
All asthma subjects completed a detailed asthma
history questionnaire, and kept a diary to record
significant medical events and changes in medications.
Healthy controls
The healthy controls underwent screening and then
baseline visit procedures, and ended their participation
in the study after the bronchoscopy visit. The study pro-
cedures for healthy controls are detailed in the protocol
linked to this report. The Phadiatop™ (Thermo Fisher
Scientific, Uppsala, Sweden) panel for specific IgE was
Fig. 1 Planned study design and sample sizes for the healthy controls and asthmatics. The study was complete after the bronchoscopy visit for
the healthy controls and after the 12 month biomarker visit for the asthmatic participants
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ometry was assessed during screening and at the base-
line and bronchoscopy visits before and after
administration of SABA. Induced sputum was performed
during screening and at the baseline visit and all healthy
controls underwent bronchoscopy.
Clinical assessments
Study case report forms
The study coordinator captured data at screening and at
each study visit using a electronic CRF which was
purpose-built for ADEPT. The data the CRF captured in-
cluded demographic characteristics, medical history, and 4
questions about asthma: 1) asthma date of diagnosis 2)
number of asthma-related ER visits in the last year 3)
number of asthma-related hospitalizations in the last year
and 4) number of asthma-related episodes requiring
additional treatment with systemic corticosteroids (IV or
oral) in the last year.
Asthmatics
Patient reported outcomes, assessed repeatedly through-
out the study, included the 7-item asthma control ques-
tionnaire (ACQ7) [12] and the asthma quality of life
questionnaire (AQLQ) [13]. A history of recent exacer-
bations was documented during screening. Spirometry
was performed according to American Thoracic Society/
European Respiratory Society (ATS/ERS) guidelines [14]
with predicted values based on NHANES III [15]. BDR
was defined as the change in FEV1 15–30 min after ad-
ministration of a SABA and assessed during screening,
and at the baseline, 3, 6, and 12 month visits. Each site
used their own spirometry equipment that conformedto ERS/ATS standards [14]. Methacholine PC20 was
performed during screening if required to confirm a
diagnosis of asthma, or at the baseline visit (only if
the pre-bronchodilator FEV1 was ≥60 % predicted).
FENO was measured at an exhalation flow rate of
50 ml/s [16] at baseline and was repeated at all visits.
In addition to the Case Report Form (CRF)-captured
variables above, an asthma history questionnaire (AHQ)
was developed which surveyed relevant details concerning
each subject’s asthma history and was used for the first
time in this protocol for exploratory evaluations. Each
subject completed the AHQ independently, and the re-
sults were captured into the electronic CRF.
Biomarker assessments
Bronchoscopic sampling
Bronchoscopy was performed in a standardized fash-
ion. Up to 6 adequate endobronchial biopsies (based
on visual inspection) were taken first, with no more
than 8 attempts at biopsy, if the subject was tolerat-
ing the procedure well. The biopsies were taken at bi-
furcations of sub-segmental airways in the lower lobe
on one side. The biopsy samples were processed im-
mediately for the required analyses using the follow-
ing sequence: 2 biopsy samples for ribonucleic acid
(RNA) isolation were be placed in RNAlater medium
(Qiagen Inc., Valencia, CA) then 2 biopsy samples for
histology-immunostaining were be placed into forma-
lin, followed by the last 2 biopsies for RNA isolation
in RNAlater. Bronchial brushings were performed after
the collection of the endobronchial biopsies. During the
brushing procedure, a small cytology brush was passed
through the bronchoscope in the lung opposite to that in
which biopsies were taken, and a small area of the airway
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ing the airway. Brushing was performed up to 6 times
depending on the patient’s tolerance of the procedure.
Each brush was passed into the airways and then
passed back and forth into sub-segmental airways of
the lower lobe 3–5 times.
Induced sputum (IS)
Induction procedure
All study participants underwent sputum induction
during screening to fulfill inclusion criteria and again at
the baseline visit. Asthmatic subjects only had a 3rd
sputum induction at the 6-month biomarker visit. Sputum
was induced for 21 min divided into three 7-min sessions
of nebulization each followed by a 3 step cleansing pro-
cedure and a focused cough attempt. An aerosol of hyper-
tonic saline (in increasing concentrations of 3, 4, and 5 %)
was generated by an ultrasonic nebulizer for inhalation by
subjects with a post-BD pre-induction FEV1 of ≥60 % pre-
dicted; for those with FEV1 ≥ 50- < 60 % predicted, induc-
tion was performed with normal/isotonic saline (0.9 %).
Subjects with a post-BD FEV1 < 50 % predicted did not
undergo induction.
Sputum processing
The plug selection method with dithiothreitol dispersal
of mucus was used for this study in all participants [17].
At the screening visit, a plug weight of at least 50 mg
and squamous cell percentages ≤ 20 % were required for
enrollment. Sputum supernatant and slides for differen-
tial cell count were prepared.
Only samples with squamous cell content ≤20 %, based
on each site’s evaluation, were included in the analyses.
Serum analytical methods
Serum was collected using standard serum separation
tubes, and frozen within 30 min. One of these frozen
aliquots, without intermediate freeze-thaw cycles, was
provided for quantification of 1129 serum analytes
using the SomaScan v3 platform (SomaLogic, Boulder,
CO; www.somalogic.com). Serum analyte levels were
reported by Somalogic as relative fluorescence units,
cross-plate calibrated, and median normalized. Analyte
levels are presented as the log2 ratio to the geometric
means of the healthy control population for further
analysis. Results for serum total immunoglobulin E
(sIgE) are presented from this panel, defining high
sIgE levels as those above the 95th percentile of the
healthy control distribution. In previous evaluations of
the platform in asthmatics and healthy controls, sIgE
measurements highly correlated (Pearson’s correlation
coefficient r > 0.9) with those obtained from standard
ELISA-based assays (data not shown).Safety
Investigators were instructed to capture adverse events
(AE) that were attributed to study procedures e.g. in-
duced sputum, bronchoscopy, etc. Emergent AEs that
were unrelated to procedures were captured at the in-
vestigators’ discretion.
Statistical considerations
Statistical analyses of clinical and biomarker data used
SAS v9 (Cary, NC) and OmicSoft ArrayStudio v7 (Cary,
NC; www.omicsoft.com). Stability of parameters over
time used a mixed linear model. No imputation was
performed for missing data. For data with log-normal
distributions (e.g., FENO, blood differential counts,
serum protein measurements), logarithm transformations
were performed. Significance of differences among
groups was evaluated using General Linear Model
analyses. P-values <0.05 were considered to be statis-
tically significant. Correlations among variables were
tested using Spearman correlation tests that do not
require assumptions of normality and linearity. Be-
cause of the large number of pair-wise comparisons
for the correlation analysis, a significance threshold of
p < 0.0004 was established by the Bonferroni adjustment
method to maintain a family-wise error rate <0.05 for the
136 pair-wise comparisons of 16 variables.
Results
Disposition
The study enrolled 30 healthy controls and 52 mild,
55 moderate, and 51 severe asthma subjects in the
USA, Canada, Romania, Denmark, Germany, France
and the United Kingdom between the years 2010–
2013 at 17 sites that were selected for their estab-
lished experience in asthma research, including ability
to perform spirometry and other study procedures
with requisite quality, and supervision by the Sponsor.
The breakdown by country/region is shown in Table 1
with approximately equal proportions derived from the
USA, Canada, EU (excluding Romania) and Romania.
Thirty subjects in each cohort underwent bronchoscopy.
All healthy control subjects completed the study and 17 of
158 asthma subjects withdrew prematurely (1 for a non-
serious AE; 5 withdrew consent, 2 for pregnancy, 4 for
sponsor decisions, 2 were lost to follow-up and 3 with-
drew for other reasons).
Demographic and clinical history from Case Report Form
(CRF)
Demographic characteristics
Detailed demographic characteristics are shown in
Table 2 by cohort and in Fig. 2 (panels a-c). Mild
asthmatics were younger than moderate and severe
asthmatics (mean ages 33.7, 45.0 and 46.2 years,
Table 2 Demographic characteristics
Cohort Healthy Controls Mild Moderate Severe Total
No. Subjects 30 52 55 51 188
USA 3 (10 %) 11 (21 %) 15 (27 %) 12 (24 %) 41 (22 %)
Canada 12 (39 %) 10 (19 %) 12 (22 %) 17 (33 %) 51 (27 %)
EU, ex-Romania 9 (29 %) 21 (40 %) 17 (31 %) 11 (22 %) 58 (31 %)
Romania 7 (23 %) 10 (19 %) 11 (20 %) 11 (22 %) 39 (21 %)
Cohort Healthy Controls Mild Moderate Severe P-value *
Age (yrs) <0.0001/<0.0001
Mean (SD) 31.6 (9.2) 33.7 (13.1) 45.0 (11.6) 46.2 (12.1)
Range (18; 54) (18; 64) (18; 65) (18; 65)
Male Sex 19 (63.3 %) 20 (38.5 %) 27 (49.1 %) 23 (45.1 %) 0.14/0.54
Race 0.43/0.27
White 27 (90.0 %) 46 (88.5 %) 47 (85.5 %) 41 (80.4 %)
Black or African American 1 (3.3 %) 1 (1.9 %) 5 (9.1 %) 7 (13.7 %)
Asian 2 (6.7 %) 4 (7.7 %) 3 (5.5 %) 2 (3.9 %)
Other 0 1 (1.9 %) 0 1 (2.0 %)
BMI (kg/m2) 0.034 /0.094
Mean (SD) 24.6 (3.4) 25.2 (3.4) 26.4 (3.5) 26.7 (4.1)
Range (17.5; 29.5) (19.4; 31.9) (18.8; 32.0) (19.1; 36.8)
Duration asthma (yrs) NA/0.094
Mean (SD) NA 17.4 (11.9) 22.0 (13.6) 22.7 (14. 0)
Range NA (0.7; 64.0) (1.5; 56.3) (0.3; 50.5)
*p-value (ANOVA F-test, or Fisher’s exact test when N, % reported) for differences across severity cohorts, including/excluding healthy control cohort
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(mean age 31.6 years). Participants who underwent bron-
choscopy were approximately 10 years younger than those
not participating in this procedure for all severity cohorts
(data not shown), in part due to restriction of their upper
age to 55 years by protocol. The mean duration of asthma
tended to be shorter in the mild asthma cohort compared
to the moderate and severe asthmatics (p = 0.21 and 0.22,
respectively). There was slight female predominance in
each asthma cohort, but male predominance in the
healthy control cohort. Mean body mass index (BMI),
which was limited by the protocol to <32 kg/m2 (ranging
from 24.6 to 26.7 kg/m2) was modestly higher in moderate
and severe asthma cohorts compared to healthy controls
(p < 0.05 for each comparison) and tended to rise with se-
verity (p = 0.094 across asthma severity cohorts, from 24.6
to 26.7 kg/m2). Obesity, defined by BMI > 30 kg/m2, in-
creased with asthma severity (p = 0.008, Armitage Test for
Trend in Proportions), from 8, 16, and 27 % of mild, mod-
erate, and severe asthma cohorts, respectively.
Assessments for allergy
A specific IgE panel (Phadiatop), assessed during screen-
ing, was negative in all healthy controls by protocol, but
positive in a vast majority of asthmatics regardless ofseverity (76, 80, and 76 % for mild, moderate, and se-
vere cohorts, respectively). Correspondingly, almost all
asthmatics had a history of allergies, determined from
the AHQ (90, 87, and 88 % for mild, moderate, and
severe cohorts, respectively). For Phadiatop positive
subjects (n = 120), 93.3 % reported a history of allergy
and 87 % had high sIgE. For Phadiatop negative sub-
jects (n = 35), 25 of 35 (71 %) still reported a history
of allergies and 16 of 35 (46 %) had high sIgE.
Prior history of asthma exacerbations
The mean number of asthma exacerbations requiring
systemic steroids in the 12 months prior to the study re-
ported by subjects to the study coordinators and cap-
tured in the case report form (CRF) was 0.3 for the mild
and moderate asthmatics cohorts, and 0.5 for the severe
cohort. The proportion of asthmatics having at least one
exacerbation in the previous year was 4 % of mild, 15 %
of moderate, and 27 % of severe asthma cohorts. Thus,
in general, the ADEPT asthma cohort was not highly
enriched for exacerbation propensity.
Medical history
The prevalence of common co-morbidities reported by
the asthmatic participants during screening derived from
Fig. 2 Demographic and clinical characteristics. The values for the indicated variables (y-axis) are shown for healthy control and asthma severity
groups (x-axis). Data presented as symbols representing individual subjects and summarized by box (inter-quartile range and median) & whiskers
(range), with ‘+’ indicating mean. Significance of differences among groups is reported in Tables 2 (for panels a-c) and 4 (for panels d-k)
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and severe severity cohorts, respectively: sinusitis (25.0,
25.5 and 27.5 %), allergic rhinitis (63.5, 50.9, and 51.0 %);
gastro-esophageal reflux (11.5, 10.9, and 23.5 %); anxiety
(7.7, 5.5, and 9.8 %); depression (3.8, 14.5, and 7.8 %).
Other common medical conditions e.g. diabetes, hyper-
tension were rare probably due to exclusion criteria.
The reported medical history for the healthy con-
trols in the CRF was as follows: sinusitis (n = 1), mi-
graine (n = 2), depression (n = 1) and other conditions
not detailed (n = 3).Asthma History Questionnaire (AHQ)
The AHQ is a non-validated patient-reported out-
come questionnaire that was developed for ADEPT,
and this was the first time it was included in a study.
A table of results from the AHQ is provided online
as Additional file 2. Data from the asthma history
questionnaire in some instances revealed discrepancies
with the data collected by the study coordinators via
the CRF. Reported p-values for AHQ are uncorrected
for multiplicity of testing and associations should be
considered exploratory.Common conditions accompanying asthma (AHQ)
Approximately 50 % of asthmatics reported having a
first degree relative(s) with asthma. Moderate and se-
vere asthmatics reported more frequently adult onset
of asthma and lung infections deemed serious by the
patient than mild asthmatics. The majority of asthma
subjects reported seasonal nasal allergies with a
greater proportion of mild asthmatics (78.8 %) com-
pared to moderate and severe asthmatics (63.6, 62.7-
%, respectively) (p = 0.079 for decreasing trend with
severity). Perennial nasal allergies were reported by
~30 % of asthmatics with no relationship to severity.
Nasal polyps were reported to a far greater degree by
severe asthmatics (29.4 %) compared to 18.2 % in
moderate and 3.8 % mild asthmatics (p < 0.0001 for
increasing trend with severity). Symptoms of gastro-
esophageal reflux, which have been associated with
asthma, were reported by ~35 % of asthmatics unre-
lated to severity. Although BMI was restricted to
<32Kg/m2, severe asthmatics reported obesity to a
greater extent (13.2 %) compared to moderate (7.3 %)
and mild (3.8 %) asthma (p = 0.069 for increasing
trend with severity). Anxiety and depression were re-
ported by 24.7 % of asthmatics unrelated to severity.
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Asthma symptoms present in the vast majority of
study participants during periods of worsening asthma
included shortness of breath, chest tightness, cough,
and audible wheezing. Expectoration of mucus during
asthma worsening was more common in moderate
and severe asthma (60.0, 60.8 %, respectively) com-
pared to mild asthma (44.2 %) (p = 0.091 for increasing
trend with severity). Nocturnal asthma was reported to a
greater degree by moderate and severe asthmatics (81.8
and 86.3 %, respectively) compared to mild asthma
(65.4 %) (p = 0.011 for increasing trend with severity).
Asthma triggers (AHQ)
The following triggers were reported by a majority of
asthmatic subjects and were unrelated to asthma se-
verity: seasonal allergens, house dust, cold air, viral
infections, and exercise. The following triggers were
reported by a majority of asthmatic subjects but were
related to asthma severity: weather conditions: moder-
ate (56.4 %) and severe (58.8 %) asthma compared to
mild (38.5 %) (p = 0.039 for increasing trend with se-
verity); irritant exposure e.g. tobacco smoke etc.:
moderate (70.9 %) and severe (78.4 %) asthma com-
pared to mild (63.5 %) (p = 0.096 for increasing trend
with severity).
Smoking history (AHQ)
All subjects had to be current nonsmokers with a
<10 pack year history, and confirmation was sought
with urinary cotinine. 32.7 % of mild, 43.6 % of mod-
erate and 39.2 % of severe asthmatics reported previ-
ous use of tobacco products, for the most part
cigarettes. The number of cigarettes smoked per day
was mostly in the 0–5 range for mild asthmatics and
the 6–10 range for moderate and severe asthmatics.
Second-hand smoke exposure at home was reported
by 69.6 % of asthmatics unrelated to severity. Only
16.4 % of asthmatics were still exposed to tobacco
smoke at home and most subjects rated this exposure
as light. Reported secondhand smoke exposure in the
workplace in the past increased with severity (p = 0.014).
Treatments for asthma (AHQ)
SABAs were used by 89.9 % of asthmatics unrelated
to severity. Mild asthmatics were not on controller
medications at the time of enrollment by protocol but
daily controller medications (current or prior) were
reported by 44.2 % of mild, 98.2 % of moderate and
94.1 % of severe asthmatics. Allergen immunotherapy
was reported by 9.6 % of mild, 10.9 % of moderate
and 15.7 % of severe asthmatics. Omalizumab was
used by 13.7 % of severe asthmatics only. Adherence
with controller medications was reported by 44.0 % ofmild, 90.9 % of moderate and 100 % of severe asth-
matics. For the mild asthmatics who were on no con-
troller medications at the time of enrollment, the
reported adherence presumably refers to prior use of
controller therapy.
Exacerbations (AHQ)
The asthma subjects reported the frequency of “in-
crease in medications for asthma worsening” which
could represent moderate exacerbations, as well as
severe-OCS-defined exacerbation. Both mild and mod-
erate asthma had similar proportion of subjects with ≥1
(46 and 42 %) and ≥2 (27 and 26 %) events per year,
compared to severe asthma which had more events
(60 % for ≥1 and 50 % for ≥2 per year; p = 0.13 and
0.0088, respectively).
Asthma disease characteristics at baseline
Table 3 reports asthma disease characteristics at the
baseline visit only (screening or baseline visit for PC20),
as mean parameters did not change over the 12 months
of the study.
Lung function
These data are presented in Fig. 2 (panels d-h) and
Table 3. The inclusion criteria were responsible in part
for the increasing severity of airflow limitation from mild
to severe asthma. Mean % predicted pre-BD FEV1 de-
clined across mild to moderate and severe asthma (92.7,
73.6, and 65.4 %, respectively; p < 0.0001); FEV1/FVC ra-
tio showed a similar pattern, with 20, 61, and 82 %, re-
spectively, of subjects having a pre-BD FEV1/FVC ratio
below 0.7. Mean post-BD FVC also fell from mild to se-
vere asthma (105.0, 96.4, and 94.0 % predicted, respect-
ively; p = 0.0004), with 2, 9, and 22 % of mild, moderate,
and severe asthmatics having a post-BD FVC of 80 %
predicted normal or below, possibly reflecting air trap-
ping. Mean BDR increased across mild to severe asthma
(8.7, 15.2, and 18.3 %, respectively; p = 0.0016). In gen-
eral, lung function was slightly better in bronchoscopy
subjects compared to non-bronchoscopy subjects (data
not shown). A similar pattern was observed at months 3,
6 and 12 (data not shown). There was no statistically sig-
nificant change in mean spirometric measures over time
for each asthma severity cohort (data not shown).
Methacholine PC20
PC20 (geometric mean, mg/mL) varied among the
asthma cohorts (p = 0.034), trending to be lower in the
severe asthma cohort (0.68 mg/ml) compared to the
mild (1.68 mg/ml, p = 0.12) and moderate (0.93 mg/ml,
p = 0.062) asthma cohorts (Fig. 2 panel i and Table 3).
Methacholine PC20 was not evaluated longitudinally.
Table 3 Asthma disease characteristics by cohort at Baseline Visit (Screening or Baseline for PC20)
Cohorts Healthy Mild Moderate Severe P-value***
N 30 52 55 51
Pre-BD FEV1 (L) 3.98 (0.81) * 3.35 (0.81) 2.39 (0.62) 2.10 (0.71) <0.0001
Pre-BD FEV1 (% predicted normal) 103.3 (13.4) 92.7 (14.3) 73.6 (10.4) 65.4 (12.7) <0.0001
Post-BD FEV1 (L) 4.10 (0.84) 3.61 (0.87) 2.67 (0.66) 2.43 (0.81) <0.0001
Post-BD FEV1 (% predicted normal) 106.2 (13.7) 101.4 (14.0) 82.7 (10.2) 75.7 (15.4) <0.0001
Pre-BD FEV/FVC ratio 0.83 (0.06) 0.77 (0.08) 0.66 (0.09) 0.61 (0.09) <0.0001
Post-BD FVC (% predicted normal) 103.8 (15.9) 105.0 (15.5) 96.4 (11.4) 94.0 (15.1) 0.0004
BDR (%) 2.9 (4.1) 8.5 (8.3) 15.2 (10.3) 18.3 (14.5) 0.0016
BDR (mL) 114.8 (140.6) 265.1 (231.7) 335.2 (234.3) 355.7 (270.6) 0.45
PC20 methacholine (mg/mL) NA 1.68 (+10.85/-0.26)** 0.93 (+6.49/-0.13)** 0.63 (+2.62/-0.15)** 0.034
ACQ7 NA 0.84 (0.69) 1.33 (0.71) 1.92 (1.01) <0.0001
Controlled ACQ <0.75 (N, %) NA 29 (56 %) 10 (18 %) 4 (8 %)
Partially controlled ACQ 0.75-1.5 (N, %) NA 13 (25 %) 24 (44 %) 16 (31 %) <0.0001
Uncontrolled ACQ≥ 1.5 (N, %) NA 10 (19 %) 21 (38 %) 31 (61 %)
AQLQ NA 5.86 (0.93) 5.68 (1.11) 5.09 (1.28) 0.0016
*Mean (standard deviation) reported by cohort, unless otherwise indicated ** Geometric mean (asymmetric standard deviation) *** p-value (ANOVA F-test, or
Fisher’s exact test when N, % reported) for differences across severity cohorts, excluding healthy control cohort (based on log-transformed data when geometric
means reported)
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Data are shown in Fig. 2 panels j-k and Table 3.
ACQ7 scores can range from 0: excellent control to
7: extremely uncontrolled [12]. At the Baseline Visit,
ACQ7 scores (mean; range) rose significantly with
asthma severity (p < 0.0001): mild (0.84; 0.00–3.4), moder-
ate (1.33; 0.1–3.9) and severe asthma (1.92; 0.4–5.7) indi-
cating that on average, subjects with mild asthma were
well-controlled, moderate asthma were partially- con-
trolled and most subjects with severe asthma were uncon-
trolled. The proportions of patients with well-controlled,
partially controlled, and uncontrolled asthma based on
ACQ rose significantly by the severity of the asthma co-
horts (p < 0.0001) as shown in Table 3.
AQLQ scores can range from 1: severe impairment to
7: no impairment [13]. For the baseline visit, AQLQ
(mean; range) fell significantly with increasing asthma
severity: mild (5.86; 3.7–7.0), moderate (5.68; 2.0–7.0)
and severe asthma (5.09; 1.4–6.8) but the proportions
of subjects with AQLQ scores under 5.0 rose with
asthma severity (p = 0.0016).
A similar pattern was observed at months 3, 6 and 12
for ACQ and AQLQ (data not shown). There was no
statistically significant change in mean values of ACQ
and AQLQ over time for each asthma severity cohort
(data not shown).
Impact of region on clinical variables
Region (US, Canada, EU-ex Romania, and Romania) had
minimal impact on the main demographic and clinical
variables reported in Tables 2 and 3. For 2 variables(pre-BD FVC, lower in mild asthmatics from Canada;
and PC20, trend for lower values in Romania), there
were nominally significant interactions (p < 0.05) be-
tween region and asthma severity cohort that did not
pass multiple testing corrections with FDR < 0.05. The
significance of associations of these 2 variables with




Mild asthmatics had less AEs compared to moderate
and severe asthmatic subjects, and subjects participat-
ing in bronchoscopy had more AEs than those not
having bronchoscopy. The % of subjects who reported
at least 1 AE were as follows: healthy controls who
were all bronchoscopy participants (10.0 %), mild asth-
matics: bronchoscopy (26.7 %), and non-bronchoscopy
participants (13.6 %), moderate asthmatics: bronchoscopy
(46.7 %), and non-bronchoscopy participants (24.0 %), and
severe asthmatics: bronchoscopy (36.7 %), and non-
bronchoscopy participants (33.3 %). SAEs occurred in 4
subjects and were all unrelated to study procedures. Pre-
ferred terms included flank pain (n = 1), adenocarcinoma
of the colon (n = 1), trigeminal neuralgia (n = 1), pleural
effusion (n = 1), and deep venous thrombosis (n = 2), with
multiple SAEs in 1 subject.
Procedure-attributed adverse events
There were no procedure-related SAEs. Subjects partici-
pating in bronchoscopy had more AEs than those not
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ported at least 1 AE were as follows: healthy controls who
were all bronchoscopy participants (10.0 %), mild asth-
matics: bronchoscopy (16.7 %), and non-bronchoscopy
participants (9.1 %), moderate asthmatics: bronchoscopy
(40.0 %), and non-bronchoscopy participants (8.0 %),
and severe asthmatics: bronchoscopy (26.7 %), and
non-bronchoscopy participants (9.5 %).
In general, the respiratory and mediastinal system-
organ class was the commonest class contributing to
procedure-related AEs with a much higher incidence in
those undergoing bronchoscopy as follows: healthy con-
trols (3.3 %), mild asthma (9.1 %), moderate asthma
(26.7 %), and severe asthma (20.0 %). Asthma was the
commonest AE occurring in 0 mild, 3.6 moderate, and
5.9 % severe asthmatics, followed in frequency by
bronchospasm and cough. Hemoptysis had a low inci-
dence (1 healthy control and 1 mild asthmatic subject).
Clinical biomarkers
Clinical biomarkers are presented in Table 4 and Fig. 3
panels a-d by severity cohort. There was no significant
impact of region on the clinical biomarkers.
FENO
At the baseline visit, geometric mean (asymptotic
standard deviation) levels of FENO (ppb) were similar
in mild (ICS-non-treated): 32.9 (+64.2/-16.9) ppb; mod-
erate: 29.1 (+61.0/-13.9) ppb; and severe asthmatics:
28.8 (+64.7/-12.9) ppb (p = 0.59 for differences among
asthma cohorts). Based on a high FENO cutoff of
35 ppb, 22/52 (42.3 %) mild, 24/54 (44.4 %) moderate,
and 14/50 (28 %) severe asthmatics had a high FENO.
Additionally, based on a low FENO cutoff of 20 ppb,
11/52 (21.1 %) mild, 24/54 (38.8 %) of moderate, and
14/50 (28 %) severe asthmatics had a low FENO.Table 4 Clinical biomarkers and sputum differential counts by coho
Cohorts Healthy Mild
n (blood/sputum) 30/20 52/32
FENO (ppb)* NA 32.9 (+64.2/-
bEOS, cells/μl* 112 (+218/-57) 178 (+347/-9
bNEU, 1000 cells/μl* 3.47 (+4.96/-2.42) 3.59 (+4.72/-
Serum IgE, RFU* 1.0 (+2.1/-0.7) 8.3 (+25.3/-6
Sputum eosinophils, % of WBC* 0.38 (+0.78/-0.25) 1.12 (+5.38/-
Sputum lymphocytes, % of WBC** 1.16 (1.05) 1.29 (1.42)
Sputum macrophages, % of WBC** 44.57 (19.42) 50.20 (31.17)
Sputum neutrophils, % of WBC** 53.57 (20.06) 43.88 (30.90)
*Geometric mean (asymmetric standard deviation) reported by cohort
**Mean (standard deviation) reported by cohort
***p-value (ANOVA F-test) for differences across severity cohorts, including/excludin
means reported)
NA = not applicable (not measured in healthy cohort)Blood eosinophils
These were measured during screening only. Of the
healthy controls, 28 of 31 (90 %) had bEOS < 300
cells/mm3 (a commonly used cutoff for “Th2” tar-
geted therapeutics), compared to 12 of 52 (23 %), 21
of 55 (38 %), and 11 of 51 (22 %) for mild, moderate,
and severe asthma. Geometric mean bEOS counts
were significantly higher in asthma (p = 0.0018 for
each asthma severity cohort vs. healthy controls) but
not significantly different among asthma severity co-
horts (p = 0.54).
Blood neutrophils
These were measured during screening only, without
significant differences among the cohorts (p = 0.35),
with geometric mean counts from 3.47, 3.59, 3.64, and
3.94 x1000/μl for healthy controls and mild, moderate,
and severe asthma cohorts, respectively.
Serum IgE
This was measured at baseline in all healthy controls
and asthma subjects, and was higher in asthmatics
compared to healthy controls (p < 0.05 for each asthma
severity cohort vs. healthy controls) but did not signifi-
cantly differ among asthma severity cohorts (p = 0.35).
Induced sputum inflammatory cells
Although sites had to meet a <20 % criteria for spu-
tum squamous cells, samples with squamous cell con-
tent ≤30 % from cytospin differential counts were
included in the analyses. A significant proportion of
subjects had only a screening or only a baseline sam-
ple available that passed quality control standards
(e.g., for cytospin slides, 105/189 possible subjects
had acceptable readings at screening, 85 acceptable at
baseline, with 128 subjects having either a screeningrt at Screening/Baseline Visits
Moderate Severe p-value***
55/38 51/40
16.9) 29.1 (+61.0/-13.9) 28.8 (+64.7/-12.9) NA/0.59
1) 197 (+435/-89) 210 (+452/-97) 0.0018/0.54
2.74) 3.64 (+4.92/-2.69) 3.94 (+5.89/-2.63) 0.35/0.32
.2) 9.8 (+26.7/-7.2) 12.1 (+31.0/-8.7) <0.0001/0.35
0.93) 3.12 (+13.62/-2.54) 2.70 (+12.27/-2.21) <0.0001/0.033
0.98 (1.19) 0.94 (1.25) 0.64/0.48
32.10 (21.45) 43.04 (26.46) 0.031/0.019
56.99 (26.13) 48.10 (25.52) 0.19/0.13
g healthy control cohort (based on log-transformed data when geometric
Fig. 3 Clinical biomarkers and sputum leukocyte differentials. The values for the indicated clinical biomarkers (panels a-d) and sputum
inflammatory cells (panels e-h) (y-axis) are shown for healthy control and asthma severity groups (x-axis). Data presented as symbols representing
individual subjects and summarized by box (inter-quartile range and median) & whiskers (range), with ‘+’ indicating mean. Significance of
differences among groups is reported in Table 4
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(differential cell counts) or geometric mean (eosino-
phil percentage) of screening and baseline measure-
ments was used for subsequent analyses of 128 of a
possible 189 subjects.
The differential inflammatory white cell counts are re-
ported in Table 4 and Fig. 3 panels e-h. Sputum eosino-
phil proportions were higher in each asthma severity
cohort vs. healthy controls (p < 0.0001) and higher in
moderate and severe asthma cohorts vs. the mild asthma
cohort (p < 0.05 for each comparison). Sputum neutro-
phil percentages were lower in mild asthma vs. healthy
controls and moderate asthma cohorts (p < 0.05 for each
comparison). Sputum macrophage proportions were
lower in moderate asthma vs. healthy controls and mild
asthma cohorts (p < 0.05 for each comparison), with a
similar trend for being lower compared to the severe
asthma cohort (p = 0.099). Sputum lymphocytes did not
significantly differ among cohorts.
Correlation between clinical and biomarker variables
Correlations between demographic, asthma clinical,
and biomarker variables are displayed in Fig. 4, report-
ing Spearman correlation coefficients. Spirometric mea-
sures were significantly inter-correlated, with preBD
FEF25-75, FEV1 % predicted, and FEV1/FVC showing
inter-correlations of r > 0.7 and preBD % predicted
FEV1 and FVC correlating with r = 0.64 (p < 0.0001).
Peak expiratory flow rate (PEFR) correlated best with the
FEF25-75 (r = 0.63, p < 0.0001) but only modestly with
FEV1 (r = 0.44, p < 0.0001). ACQ7 showed a significantnegative correlation with AQLQ (r = −0.73, p < 0.0001)
and FEV1 (r = −0.59, p < 0.0001). BDR showed a negative
correlation with PC20 (r = −0.44, p < 0.0001). Blood eosin-
ophils were only weakly correlated to FENO (r = 0.30,
p = 0.0001) and spEOS (r = 0.37, p < 0.0001), with
FENO demonstrating a trend for stronger correlation to
spEOS (r = 0.41, p < 0.0001). Among the clinical variables
evaluated, PC20 (r = −0.33, p = 0.0011) and BDR (r = −0.29,
p = 0.0027) had the best, albeit very modest, correlations to
spEOS. Blood neutrophil and macrophage counts were
moderately correlated (r = 0.50, p < 0.0001), though neither
were associated with asthma severity.
Despite the trends described above for the relationship
of asthma disease characteristics with disease severity, the
correlations between parameters were generally modest
between different classes of clinical measurements.
Discussion
The ADEPT study successfully profiled mild, moderate,
and severe asthma compared to non-atopic controls with
an acceptable safety profile for the invasive procedures.
Although a moderately sized study, ADEPT accrued bio-
marker data across multiple matrices in the majority of
subjects and evaluated several of these matrices repeatedly
over 12 months.
The definitions of mild, moderate and severe asthma
deviated somewhat from accepted definitions for the fol-
lowing reasons. Mild asthmatics were required to be off
controller medications to allow evaluation of disease-
related biomarkers without the impact of corticosteroids
resulting in a very mild asthma cohort. The moderate
Fig. 4 Correlation matrix across clinical and biomarker measures. Spearman correlation coefficients are reported for the pairing of variables
indicated on the y-axis vs. x-axis, using values from asthma subjects only (healthy controls excluded) from baseline visit, for blood differentials
from the screening visit, and for PC20 from either the screening or baseline visit. Color scale ranges from blue (r = −1) to white (r = 0) to red (r = 1).
P- values <0.05 were considered to be statistically significant. Correlations among variables were tested using Spearman correlation tests that do not
require assumptions of normality and linearity. Because of the large number of pair-wise comparisons, a significance threshold of p < 0.0004
was established by the Bonferroni adjustment method to maintain a family-wise error rate <0.05 for the 136 pair-wise comparisons of 16 variables
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dose rather than lung function, primarily for practical
reasons. For safety reasons in subjects undergoing inva-
sive procedures, asthmatics were required to be free of
recent exacerbations, to have no history of life-threatening
asthma and BMI was limited to <32 kg/m2. Despite this
limitation, obesity defined by a BMI >30 kg/m2 was in-
creasingly prevalent in moderate and severe compared to
mild asthma. Other studies have also identified a subset of
asthmatics with obesity where distinct biological mecha-
nisms may be driving disease severity [18–20].
The asthmatic bronchoscopy subset was restricted to
age <55 years and this resulted in a significantly younger
population by approximately 10 years. All participants in
ADEPT had to be current nonsmokers (confirmed by
urinary cotinine levels) to remove the confounding effect
of tobacco smoke on biomarkers. We required healthy
controls to be non-atopic by a specific IgE panel to pro-
vide a suitable contrast to asthmatics, who were in gen-
eral atopic. The ADEPT severity definitions resulted in
cohorts that differed in severity for multiple clinical pa-
rameters thus confirming their utility.The methods of assessing allergic disposition were
not in perfect agreement as might be expected from
subjective (history by AHQ) and objective testing
(sIgE, Phadiatop). The Phadiatop panel is composed of
specific IgE against a panel of allergens for each re-
gion and is reported as a dichotomous variable. It is
possible that low recent exposure could suppress titers
or that relevant allergens were not captured for each
subject.
Inclusion and exclusion criteria (see Additional file 1
linked to this report) were in part responsible for redu-
cing the frequency of exacerbations. Although the mean
number of severe exacerbations reported on the case re-
port form (CRF) was low, 27 % of the severe asthmatics
reported at least 1 OCS-treated exacerbation in the prior
year. The AHQ presented additional data for “worsening
of asthma requiring increase in medications” in that
mild and moderate asthmatics had similar proportions
of subjects with at least 1 event in contrast to severe
asthma (60 %). This suggests that the inclusion criteria
by asthma severity applied in ADEPT, and in particular
the dose of ICS, succeeded to enrich for disease burden.
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study, and it should be regarded as an unvalidated in-
strument. Notwithstanding, the AHQ provided a more
comprehensive insight into asthma history than that
captured by the study coordinators in the CRF and
highlighted some important differences between the
asthma severity cohorts. Of note, the moderate and se-
vere asthmatics had adult onset of disease more fre-
quently than mild asthma, and reported more serious
lung infections compared to mild asthma. Thus infection
might be a driver for asthma severity. The discordance be-
tween allergy history by AHQ and CRF is discussed above.
The increased prevalence of seasonal nasal allergy in
mild asthma suggests that this might remit over time.
Severe asthmatics reported nasal polyps more fre-
quently, raising the possibility of aspirin sensitivity driv-
ing severity that has been reported to be associated
with exacerbations [21]. The self-reported prevalence of
obesity was highest in severe asthma but much less
than BMI categorization, perhaps related to subject
denial. The prevalence of nocturnal asthma was related
to severity as has been previously recognized. Self-
reported adherence to controller medications improved
with worsening severity as might be expected.
Asthma disease characteristics present a more objective
perspective on asthma severity and in general worsened
with asthma severity in part dictated by inclusion criteria.
Of note, the decrement in post-BD FVC in severe asthma
is suggestive of air trapping perhaps related to more sig-
nificant small airway disease [22] and/or loss of elastic re-
coil [23]. Inclusion/exclusion criteria were designed to
exclude recently unstable but not necessarily poorly con-
trolled asthma. Indeed, an objective was to enroll patients
in the moderate and severe cohorts that were not ad-
equately controlled by ICS based on persistent obstruction
(FEV1 < 80 % predicted), corresponding to common
therapeutic interventional clinical trials enrollment re-
quirements. Accordingly, a significant proportion of the
moderate (38 %) and severe asthma (61 %) cohorts were
uncontrolled based on the ACQ-7 cut-off of 1.5.
Clinical biomarkers in ADEPT were selected for clinical
practicality, with the exception of induced sputum which
is not widely available. FENO levels were not different by
asthma severity in agreement with one study [24] but in
contrast to others [25, 26], perhaps related to less severe
asthma in ADEPT and better response to ICS. Even
though the mild asthmatics were not treated with inhaled
corticosteroids, the absence of more elevated FENO may
be due to a low inflammatory burden in this cohort.
The number of subjects who had valid sputum sam-
ples available for analysis was approximately 70 % for
the screening and/or baseline visits despite consider-
able efforts to use experienced research sites and to
train sites and subjects. The success rate in ADEPTwhich involved multiple centers, was less than that
achievable in highly specialized single centers [27, 28]
as might be expected. This illustrates that sputum in-
duction as well as processing are technically complicated
especially in a multicenter setting and probably not applic-
able to larger studies or clinical application, thus limiting
utility.
Moderate and severe asthmatics had a significantly
greater percentage of sputum eosinophils, and a trend for
increase in % sputum neutrophils compared to mild and
healthy controls despite treatment with ICS, but a signifi-
cantly lower percentage of sputum macrophages. The per-
sistence of sputum eosinophils in the moderate and severe
asthmatics suggests a residual inflammatory burden that
could be related to multiple factors e.g. ICS dose, ICS de-
livery to the airways, severity of disease, steroid resistance,
and last but not least, patient adherence, which was not
verified by objective means in ADEPT.
In general, the paucity of associations between mul-
tiple asthma characteristics may be due to distinct
asthma domains e.g. lung function, inflammation, and
patient history and experience. Of note, the weaker than
expected correlation between bEOS and FENO and
spEOS and blood perhaps related to the effect of ICS on
FENO and spEOS, and less than on bEOS. Supporting
this is the better correlation between FENO and spEOS
as described previously [29, 30]. Eosinophilic inflamma-
tion assessed in sputum, but not in blood, showed weak
correlations with worse AHR and a greater BDR which
is in keeping with eosinophilic inflammation reflecting
an at-risk phenotype [24].
European studies profiling efforts include ENFUMOSA
(European Network for Understanding Mechanisms of
Severe Asthma) [31] established in the mid-90s.
ENFUMOSA, a multicenter cross sectional study, en-
rolled 163 patients with severe asthma and compared
these to 158 mild asthma patients. A subset of sub-
jects underwent induced sputum but bronchoscopy
was not included. Important insights with regard to
severe asthma from ENFUMOSA include persistent
decrements in lung function and symptoms despite
therapies, neutrophilic inflammation and identification
of risk factors for severe asthma and near-fatal asthma.
Subsequently, BIOAIR (Longitudinal Assessment of Clin-
ical Course and BIOmarkers in Severe Chronic AIRway
Disease [32]), an offshoot from ENFUMOSA, enrolled
mild (n = 93), and severe asthma patients (n = 76) [33].
After optimization of inhaled therapy, patients were en-
rolled in a double blind 2 week trial of OCS versus pla-
cebo, followed by a one year follow up. The study revealed
that spEOS and FENO were the best predictors of favor-
able response to oral prednisolone in severe asthmatics.
The Severe Asthma Research Program (SARP) is the
biggest severe asthma program to date. In a review from
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a multicenter setting, of which 582 subjects had severe
asthma. Subsets of these subjects underwent induced spu-
tum evaluation [35] and 505 subjects including 151 severe
asthma subjects underwent bronchoscopic sampling [34]
with gene expression studies by way of example revealing
novel phenotypes and pathways associated with FENO
elevation [36]. Key findings from SARP have been
reviewed periodically [34, 37], and clustering has been per-
formed on subsets from this program [35, 38, 39] resulting
in important insights into asthma phenotypes. Unlike
ADEPT, SARP has included CT imaging in 424 subjects
and MRI with hyperpolarized helium which has allowed
evaluation of structure function relationships.
The more recent “Unbiased BIOmarkers in PREDiction
of respiratory disease outcomes” (U-BIOPRED) consor-
tium [40] has evaluated adult and pediatric asthmatic
subjects with subsets also performing induced sputum
and undergoing bronchoscopy. U-BIOPRED has a greater
representation of refractory asthmatics treated with
chronic OCS, and smoking asthmatics, than ADEPT,
while pediatric patients were also enrolled. The study co-
horts and biomarkers have been recently reported [41].
Limitations of the ADEPT population are predomin-
antly due to protocol-mandated restrictions. Thus ADEPT
did not include the most refractory asthmatic subjects
(predominantly due to restrictions on lung function and
recent exacerbations), currently smoking asthmatics (and
those with > 10 pack year history), those with morbid
obesity, and only 1 severe subject was treated with chronic
OCS. Additionally, ADEPT did not include pediatric
asthma and non-Caucasian representation was small.
Finally, the enrollment of asthma subjects from different
regions with varying geographies, ethnic composition and
health-care delivery could have resulted in heterogeneity.
However, there were few variables that were observed to
be significantly impacted by regional differences.
Conclusions
The ADEPT study evaluated multiple matrices including
induced sputum and bronchoscopic sampling, and state
of the art biomarker assessments. The ADEPT study en-
rolled the planned numbers of asthmatics across a range
of severity, as well as non-atopic controls. Study proce-
dures, including induced sputum and fibreoptic bron-
choscopy, were performed safely. Clinical characteristics
and biomarkers were differentiated in general by severity
as intended. Future directions include overlaying gene
expression profiles in airway samples and other matrices
on the severity cohorts, and applying clustering methods
to subset subjects and identify differential biology. The
ADEPT data promises to be a rich repository that will
help identify biological endotypes and help develop per-
sonalized therapies for asthma.Additional files
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